Comparing Four AI-Powered Drug Discovery Stocks
A technology like artificial intelligence (AI) is extraordinarily complex to begin with. When you start to apply AI to complex domains like drug discovery, there’s a snowball’s chance in hell your average retail investor will understand what’s happening under the hood. If, as risk-averse investors, we adhere to Warren Buffett’s adage of only investing in what we understand, this puts us in a difficult position.
One way to break down the complexity of a company is by examining their business model. Without revenues, it’s practically impossible to properly examine a business model, which is why we don’t invest pre-revenue. Today, we’re going to look at four different publicly traded companies that are using AI to improve the drug discovery process.
Four AI Drug Discovery Stocks
| Company Name | Ticker | Market Cap (USD billions) |
| Exscientia | TBD | TBD |
| AbCellera | ABCL | 5.67 |
| Schrodinger | SDGR | 4.42 |
| Recursion Pharmaceuticals | RXRX | 4.52 |
Artificial intelligence algorithms are great fo
